Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö > ¹ÙÀÌ¿ÀÀåºñ > ½Å±Ô ÀÀ°í °Ë»ç ±â¼ú°ú ½ÃÀå¿¡¼­ÀÇ ÀÀ¿ë
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1593)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (51)
¹ÙÀÌ¿À¸¶Ä¿ (155)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (54)
¹ÙÀÌ¿ÀÀåºñ (359)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (131)
À¯ÀüÀÚ Ä¡·á/RNAi (101)
Àç»ýÀÇÇÐ (125)
Ç×ü/¸é¿ª (191)
½ÃÀ庸°í¼­

½Å±Ô ÀÀ°í °Ë»ç ±â¼ú°ú ½ÃÀå¿¡¼­ÀÇ ÀÀ¿ë

Emerging Coagulation Testing Technologies and Market Applications

¸®¼­Ä¡»ç Venture Planning Group
¹ßÇàÀÏ 2011³â 12¿ù »óǰÄÚµå 225039
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 1,850 £Ü 2,196,800 PDF by E-mail (Local license)
US $ 4,100 £Ü 4,868,700 PDF by E-mail (Global license)


Venture Planning Group ¿¡¼­ 2011³â 12¿ù ¿¡ ¹ßÇàÇÑ ¡¸½Å±Ô ÀÀ°í °Ë»ç ±â¼ú°ú ½ÃÀå¿¡¼­ÀÇ ÀÀ¿ë¡¹ º¸°í¼­´Â US $1,850 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

ÀÀ°í °Ë»ç ±â¼ú¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ¹ß»ö ±âÁú, ¸ð³ëŬ·Î³Î Ç×ü¿Í Æú¸®Å¬·Î³Î Ç×ü, ¸é¿ªÃøÁ¤¹ý µî ÇöÀç ¹× ½Å±Ô ÀÀ°í °Ë»ç ±â¼ú°ú ÀáÀçÀûÀÎ ½ÃÀå¿¡¼­ÀÇ ÀÀ¿ë¿¡ ´ëÇØ ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Á¦1Àå ¹ß»ö ±âÁú

Á¦2Àå ¸ð³ëŬ·Î³Î Ç×ü¿Í Æú¸®Å¬·Î³Î Ç×ü

Á¦3Àå ¸é¿ªÃøÁ¤¹ý

  • ÀÀ¿ë
  • ±â¼úÀû ¿ø¸®
  • È¿¼Ò ¸é¿ªÃøÁ¤¹ý(EIA)
    • °³¿ä
    • ELISA
    • EMIT
    • ´å ¸é¿ª °áÇÕ ¾Ñ¼¼ÀÌ
    • ¸ð¼¼Ç÷°ü ¸é¿ªÃøÁ¤¹ý
    • È¿¼Ò ÁõÆø
    • Àü±â È­ÇÐ ¸é¿ªÃøÁ¤¹ý
  • Çü±¤ ¸é¿ªÃøÁ¤¹ý(FIA)
    • Çü±¤ Æí±¤
    • ½Ã°£ ºÐÇØ ÆÞ½º Çü±¤
    • Çü±¤ ¼ö¸í
  • ¶óÅØ½º ÀÀÁý¹ý(LA)
  • ¸é¿ª ħ°­¹ý

Á¦4Àå ¸¶ÀÌÅ©·ÎÄÄÇ»ÅÍ

Á¦5Àå ÀÚµ¿È­

Á¦6Àå ·Îº¿ °øÇÐ

Á¦7Àå DNA ÇÁ·Îºê

  • °³¿ä
  • ÁõÆø¹ý
    • Æú¸®¸Ó¶óÁ¦ ¿¬¼â ¹ÝÀÀ(PCR)
    • ¸®°¡Á¦ ¿¬¼â ¹ÝÀÀ(LCR)
    • ºÐ±â DNA
    • Q¥â¸®Çø®Ä«Á¦
    • ÇÙ»ê ¹è¿­ ±â¹Ý ÁõÆø(NASBA)
    • SDA
    • 3 SR
    • HPA
    • 2Ãþ ½Ã½ºÅÛ
    • LAT

Á¦8Àå ÀΰøÁö´É(AI)

Á¦9Àå µå¶óÀÌ Äɹ̽ºÆ®¸®

Á¦10Àå ¹ÙÀÌ¿À¼¾¼­

KSA
Back to Top